Diabetes Patents (Class 514/6.9)
-
Patent number: 8999927Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.Type: GrantFiled: April 2, 2013Date of Patent: April 7, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Qing-Rong Liu
-
Patent number: 8999940Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.Type: GrantFiled: August 7, 2009Date of Patent: April 7, 2015Assignee: Ipsen Pharma S.A.S.Inventor: Zheng Xin Dong
-
Publication number: 20150093370Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventors: Yoram SHECHTER, Matityahu FRIDKIN
-
Patent number: 8993517Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: June 27, 2013Date of Patent: March 31, 2015Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
-
Publication number: 20150087585Abstract: Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.Type: ApplicationFiled: March 26, 2013Publication date: March 26, 2015Applicant: PFIZER INC.Inventors: Kay Ahn, Markus Boehm, Shawn Cabral, Philip A. Carpino, Kentaro Futatsugi, David Hepworth, Daniel W. Kung, Suvi Orr, Jian Wang
-
Publication number: 20150087586Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: March 25, 2013Publication date: March 26, 2015Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8987197Abstract: Novel PEGylated insulin analogs exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogs contain B25H and A14E or A14H. The PEGylation is at B29K.Type: GrantFiled: November 29, 2011Date of Patent: March 24, 2015Assignee: Novo Nordisk A/SInventors: Peter Madsen, Thomas Hoeg-Jensen, Thomas Børglum Kjeldsen, Tina Møller Tagmose
-
Patent number: 8987198Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.Type: GrantFiled: December 22, 2010Date of Patent: March 24, 2015Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLCInventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
-
Publication number: 20150080294Abstract: The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating catestatin in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject.Type: ApplicationFiled: April 1, 2013Publication date: March 19, 2015Inventors: Sushil K. Mahata, Gautam K. Bandyopadhyay
-
Publication number: 20150079094Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.Type: ApplicationFiled: September 12, 2014Publication date: March 19, 2015Inventors: Joyce Tombran-Tink, Colin J. Barnstable
-
Publication number: 20150080288Abstract: Nitration shielding peptides that reduce or prevent nitration of a protein of interest are disclosed. The peptide can serve as molecular sink for nitrating agents, block access of the nitrating agents to the target tyrosine on the protein of interest, serve as substrate for the nitrating agent (i.e., provide an alternative nitratable tyrosine residue), provide a nitrating agent neutralizing moiety such as antioxidant, or a combination thereof. The nitration shielding peptide can be a fusion protein that includes one or more additional domains such a protein transduction domain, a targeting signal, a purification tag, or any combination thereof. Exemplary nitration shielding peptides for reducing nitration of RhoA and PKG-1?, and methods of use thereof for treating pathologies, disease, and disorders associated with nitration of RhoA and PKG-1?, respectively are also provided.Type: ApplicationFiled: September 15, 2014Publication date: March 19, 2015Inventors: Stephen M. Black, Ruslan Robertovich Rafitov
-
Patent number: 8980249Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.Type: GrantFiled: June 3, 2011Date of Patent: March 17, 2015Assignees: University of Miami, Dresden University of TechnologyInventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
-
Patent number: 8980822Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: June 29, 2012Date of Patent: March 17, 2015Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 8980830Abstract: Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix is stabilized.Type: GrantFiled: October 27, 2008Date of Patent: March 17, 2015Assignee: Indiana University Research and Technology CorporationInventors: Richard D. Dimarchi, Bin Yang, Chenguang Ouyang
-
Patent number: 8980244Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: April 15, 2013Date of Patent: March 17, 2015Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Publication number: 20150072925Abstract: The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates. The composition induces body weight loss when administered to a subject as the only source of nutrition for at least 12 hours.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Inventor: Oliver R. DI PIETRO
-
Patent number: 8975224Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.Type: GrantFiled: June 24, 2013Date of Patent: March 10, 2015Assignee: Serpin Pharma, LLCInventors: Soren Mogelsvang, Cohava Gelber
-
Patent number: 8975223Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.Type: GrantFiled: December 22, 2011Date of Patent: March 10, 2015Assignee: Marcadia Biotech, Inc.Inventors: Louis Vignati, Richard D. DiMarchi
-
Publication number: 20150065424Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.Type: ApplicationFiled: November 17, 2014Publication date: March 5, 2015Applicant: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Patent number: 8969294Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: August 6, 2012Date of Patent: March 3, 2015Assignees: Istituto di Recerche di Biologia Molecolare P. Angeletti S.R.L., Indiana University Research and Technology CorporationInventors: Elisabetta Bianchi, Antonello Pessi, Jonathan Day, Richard Dimarchi, David Smiley
-
Publication number: 20150056167Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.Type: ApplicationFiled: September 4, 2014Publication date: February 26, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150057219Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8961982Abstract: Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively modulating the fetal programming of the immune system for the purpose of preventing or treating immune-modulated diseases. The disclosure also provides interventions to protect offspring and immunized subjects against insulin resistance.Type: GrantFiled: June 13, 2008Date of Patent: February 24, 2015Assignee: The Regents of the University of CaliforniaInventors: Wulf Palinski, Tomoya Yamashita
-
Publication number: 20150051143Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.Type: ApplicationFiled: March 13, 2014Publication date: February 19, 2015Applicant: Mochida Pharmaceutical Co., LTDInventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
-
Publication number: 20150051146Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.Type: ApplicationFiled: March 19, 2013Publication date: February 19, 2015Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
-
Publication number: 20150045296Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.Type: ApplicationFiled: March 15, 2013Publication date: February 12, 2015Applicant: XAVIER UNIVERSITY OF LOUISIANAInventor: Partha S. Bhattacharjee
-
Patent number: 8951962Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.Type: GrantFiled: May 17, 2013Date of Patent: February 10, 2015Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Karthryn S. Prickett, Andrew A. Young
-
Publication number: 20150038402Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
-
Publication number: 20150038412Abstract: This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor.Type: ApplicationFiled: January 18, 2013Publication date: February 5, 2015Inventors: Nikhil V. Dhurandhar, Rashmi Krishnapuram
-
Publication number: 20150038411Abstract: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.Type: ApplicationFiled: February 22, 2013Publication date: February 5, 2015Applicant: Immundiagnostik AGInventor: Thomas Dschietzig
-
Patent number: 8946154Abstract: Peptide derivatives, their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstr1, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.Type: GrantFiled: May 6, 2010Date of Patent: February 3, 2015Assignee: BCN Peptides, S.A.Inventors: Antonio Parente Dueña, Berta Ponsati Obiols, Jimena Fernández Carneado, Marc Gómez Caminals, Ribera Jordana I Lluch
-
Patent number: 8946147Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.Type: GrantFiled: June 23, 2011Date of Patent: February 3, 2015Assignee: Indiana University Research and Technology CorporationInventors: Richard D. DiMarchi, Binbin Kou, Shujiang Cheng
-
Publication number: 20150031604Abstract: The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Frederic ZECRI, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Jun Yuan, Aimee Richardson USERA, Changgang LOU, Aaron KANTER, Alexandra Marshall BRUCE, Carla Giumaraes
-
Publication number: 20150030595Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: ApplicationFiled: January 3, 2013Publication date: January 29, 2015Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Patent number: 8940691Abstract: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.Type: GrantFiled: March 18, 2013Date of Patent: January 27, 2015Inventors: Avadhesha Surolia, Sarika Gupta, Mahendra Pal Singh, Tandrika Chattopadhyay
-
Patent number: 8940316Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.Type: GrantFiled: November 15, 2010Date of Patent: January 27, 2015Assignee: Intarcia Therapeutics, Inc.Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
-
Publication number: 20150023960Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
-
Publication number: 20150025002Abstract: The invention relates to peptides and peptide derivatives based on the naturally occurring peptide xenin. The invention provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence, the peptide having one or more lysine residues substituted with a lipophilic substituent of 840 carbon atoms, optionally via a spacer. The present invention also provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence and in which one or more of Lys4, Lys8, Arg11, Lys13, Phe17, Lys20, or Arg21 have been replaced with another amino acid which increases resistance of the peptide to enzymatic degradation. Further provided are molecules and formulations comprising these peptides and therapeutic uses of these peptides.Type: ApplicationFiled: January 14, 2013Publication date: January 22, 2015Inventors: Victor Alan Gault, Nigel Irwin, Peter Flatt
-
Publication number: 20150018272Abstract: Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof.Type: ApplicationFiled: August 22, 2014Publication date: January 15, 2015Inventors: Claresa S. Levetan, Victor M. Garsky, Loraine V. Upham
-
Publication number: 20150018267Abstract: The invention provides compositions and methods for utilizing endomucin as an anti-inflammatory AgentType: ApplicationFiled: August 6, 2012Publication date: January 15, 2015Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE, INC.Inventors: Patricia A. D'Amore, Pablo Argüeso, Alisar S. Zahr
-
Publication number: 20150018271Abstract: The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60), and for suppression, prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™, a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression, prevention or treatment of T2D.Type: ApplicationFiled: February 28, 2013Publication date: January 15, 2015Inventors: Irun R. Cohen, Raanan Margalit
-
Patent number: 8932559Abstract: Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.Type: GrantFiled: October 5, 2012Date of Patent: January 13, 2015Assignee: Vanderbilt UniversityInventors: Jack J. Hawiger, Robert D. Collins, Daniel J. Moore, Jozef Zienkiewicz, Ruth Ann Veach
-
Publication number: 20150011469Abstract: Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed, wherein the methods and compositions of the invention are based on the use of non-glycosylated apolipoprotein A-IV produced by a protein expression system, such as a bacterial expression system. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof based on administering non-glycosylated apolipoprotein A-IV produced by a protein expression system.Type: ApplicationFiled: November 21, 2012Publication date: January 8, 2015Inventors: Patrick Tso, Fei Wang, Sean Davidson
-
Publication number: 20150010508Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.Type: ApplicationFiled: July 21, 2014Publication date: January 8, 2015Inventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20150011466Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: January 9, 2013Publication date: January 8, 2015Inventors: Thomas J. McMurry, Richard J. Looby
-
Publication number: 20150011458Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).Type: ApplicationFiled: June 17, 2014Publication date: January 8, 2015Inventors: Jan-Eric Ahlfors, Khalid Mekouar
-
Publication number: 20150010531Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.Type: ApplicationFiled: July 31, 2014Publication date: January 8, 2015Applicant: ANNEXIN PHARMACEUTICALS ABInventors: Johan FROSTEGÅRD, Knut PETTERSSON
-
Publication number: 20150011470Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.Type: ApplicationFiled: September 19, 2014Publication date: January 8, 2015Applicant: PFIZER INC.Inventors: Mary Theresa Didiuk, Robert Lee Dow, David Andrew Griffith
-
Patent number: 8927274Abstract: A method of generating pancreatic progenitor cells is disclosed. The method comprises: (a) differentiating stem cells under conditions such that at least a portion of the cells express glucose transporter 2 (GLUT2) so as to generate GLUT2-expressing cells; and (b) enriching for the GLUT2-expressing cells so as to generate a population of GLUT2 enriched cells, wherein at least 80% of the population of GLUT2 enriched cells express GLUT2, thereby generating pancreatic progenitor cells. Isolated populations of cells generated according to the method, pharmaceutical compositions comprising same and uses thereof are also disclosed.Type: GrantFiled: April 12, 2011Date of Patent: January 6, 2015Assignee: Technion Research & Development Foundation LimitedInventors: Joseph Itskovitz-Eldor, Bettina Fishman, Hanna Segev
-
Patent number: 8927488Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: GrantFiled: May 17, 2011Date of Patent: January 6, 2015Assignee: Cebix, Inc.Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni